MorphoSys AG with ticker code (MOR) have now 4 analysts in total covering the stock. The consensus rating is pointing to ‘Hold’. The target price High/Low ranges between 14.98 and 2.9 calculating the mean target price we have $6.08. Given that the stocks previous close was at $5.17 and the analysts are correct then there would likely be a percentage uptick in value of 17.6%. Also worth taking note is the 50 day moving average now sits at $4.43 and the 200 day moving average is $4.69. The market cap for the company is $692m. You can visit the company’s website by visiting: https://www.morphosys.com
The potential market cap would be $814m based on the market consensus.
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignanciesluding diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule to treat myelofibrosis; Felzartamab, an antibody directed against CD38 for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule to promote anti-tumor activity by inhibiting EZH2 and EZH1. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer’s diseases; and Otilimab, an antibody for rheumatoid arthritis. The company has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.
The company is not paying dividends at this time.
